Wedbush Reiterates Outperform on Keros Therapeutics, Maintains $86 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has reiterated an 'Outperform' rating on Keros Therapeutics (NASDAQ:KROS) and maintained a price target of $86.
August 31, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst maintains 'Outperform' rating on Keros Therapeutics and keeps the price target at $86.
The reiteration of the 'Outperform' rating and the maintenance of the $86 price target by Wedbush analyst Andreas Argyrides indicates a positive outlook for Keros Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100